Sanofi and Lonza have entered into a strategic partnership to build and operate a large-scale mammalian cell culture facility for monoclonal antibody production in Visp, Switzerland. The strategic partnership in the form of a joint venture combines the biologics development pipeline of Sanofi with the Lonza’s capability to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility. The initial investment will be approximately $285 million to be split e...